No profile data available.
GlucoTrack, Inc. (GCTK) is a healthcare company in the chemical laboratory testing equipment industry, based in Rutherford, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$19.39 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Europe was its largest region in fiscal year 2019, with 100% of revenue. Its market capitalization was $1.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
GlucoTrack reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
Europe: 100% of revenue by region in fiscal year 2019, followed by Asia and Pacific (under 1%).
$1.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (chemical laboratory testing equipment) include Intelligent Bio Solutions Inc. (INBS), Bluejay Diagnostics, Inc. (BJDX), Axim Biotechnologies, Inc. (AXIM), T2 Biosystems, Inc. (TTOO).